Randomized phase II trial of irinotecan and bevacizumab as neo-adjuvant and adjuvant to temozolomide-based chemoradiation compared with temozolomide-chemoradiation for unresectable glioblastoma: final results of the TEMAVIR study from ANOCEF†

authors

  • Chauffert B.
  • Feuvret L.
  • Bonnetain F.
  • Taillandier L.
  • Frappaz D.
  • Taillia H.
  • Schott R.
  • Honnorat J.
  • Fabbro M.
  • Tennevet I.
  • Ghiringhelli F.
  • Guillamo J.
  • Durando X.
  • Castera D.
  • Frenay M.
  • Campello C.
  • Dalban C.
  • Skrzypski J.
  • Chinot O.

document type

ART

more information